Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.
ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.
The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.
Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).
Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.
ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.
Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.
ImmunityBio, Inc. (NASDAQ: IBRX) has announced a registered direct offering to institutional investors, aiming to raise approximately $50 million in gross proceeds. The financing involves the issuance of common stock and warrants for additional shares, potentially generating up to $60 million if the warrants are fully exercised. This funding is intended to bolster working capital and support ongoing operations. Jefferies LLC acts as the exclusive placement agent for the offering. ImmunityBio is focused on developing innovative immunotherapies targeting cancers and infectious diseases, with its lead candidate N-803 currently under FDA review for bladder cancer.
ImmunityBio, identified by NASDAQ: IBRX, announced positive outcomes from its Phase 2 study on metastatic pancreatic cancer, QUILT 88. The study involved 83 patients and showed a median overall survival (OS) of 5.8 months, significantly higher than historical rates of 2-3 months. In the third-line cohort, the median OS reached 6.3 months. Notably, 61% of patients demonstrated disease control. The company held discussions with the FDA regarding registration pathways for pancreatic cancer and NMIBC. A randomized trial is in place for second-line patients, with 25 enrolled to date.
ImmunityBio has secured approximately
LadRx Corporation (OTCQB: LADX) provides a quarterly update for Q3 2022, highlighting its biopharmaceutical advancements, particularly in cancer therapeutics. The company focuses on its LADR technology, enabling targeted chemotherapeutic delivery. Key developments include the next-gen LADR drug candidates LADR7-10 and the progress of Aldoxorubicin, now in clinical trials under Immunity Bio (NASDAQ: IBRX). Financially, LadRx aims to extend its cash runway into mid-2023 while seeking additional funding amidst challenging market conditions.
ImmunityBio, Inc. (NASDAQ: IBRX) announced its participation in the 34th Annual Piper Sandler Healthcare Conference in
ImmunityBio's QUILT 3.032 trial results for N-803 plus BCG show promising efficacy for bladder cancer patients. In the carcinoma in situ cohort, 71% achieved complete response (CR) with a median duration of 26.6 months. The treatment demonstrated a 90% probability of avoiding cystectomy in responders. In the NMIBC cohort, 55% remained disease-free at 12 months. The FDA is reviewing the Biologics License Application for this combination therapy, with a decision expected by May 23, 2023. N-803's safety profile was comparable to BCG alone, indicating its potential role in treating BCG-unresponsive bladder cancer.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, will present at the Jefferies London Healthcare Conference in London from November 15-17, 2022. The presentation is scheduled for November 15 from 4:25–4:55 PM BST and will include a corporate presentation followed by a Q&A session. A webcast link for the presentation is available online, and a replay will be archived for 90 days. ImmunityBio is focused on developing therapies and vaccines to enhance the immune system against cancers and infectious diseases, with a clinical pipeline of 27 trials.
Faraday Future has appointed Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Han replaces Becky Roof, who served in the interim role until October 12, 2022. The company expects to receive $10 million this week as part of a $60 million financing agreement, following the successful acquisition of $55 million in financing. The funds will support Faraday Future’s operations and its efforts to bring the FF 91 to market. CEO Dr. Carsten Breitfeld expressed confidence in Han’s experience and the company’s growth potential.
The FDA has accepted ImmunityBio's Biologics License Application (BLA) for N-803, an IL-15 superagonist, targeting BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This marks a significant milestone for ImmunityBio as it is their first BLA submission. The application is supported by positive results from the QUILT 3.032 trial, where 71% of patients exhibited a complete response, with a median response duration of 26.6 months. The target action date for FDA review is May 23, 2023.
ImmunityBio has released positive data from pivotal clinical trials for treatments in bladder cancer and advanced pancreatic cancer, presented at the ASCO Annual Meeting. In bladder cancer, 71% of patients achieved a complete response, with a median duration of 26.6 months, and a 91% rate of avoiding cystectomy. In pancreatic cancer, the Nant Vaccine doubled median overall survival to 6.2 months. The company is advancing combination immunotherapy strategies and aims to launch additional trials in earlier treatment settings.
FAQ
What is the current stock price of ImmunityBio (IBRX)?
What is the market cap of ImmunityBio (IBRX)?
What does ImmunityBio, Inc. specialize in?
What are the key product candidates of ImmunityBio?
Which cancers does ImmunityBio focus on treating?
What geographical segments does ImmunityBio operate in?
What types of therapies is ImmunityBio developing?
How does ImmunityBio's Anktiva work?
What recent achievements has ImmunityBio made?
Where can I find the latest news about ImmunityBio?
What is ImmunityBio's business model?